during the fast evolving discipline of oncology analysis, correct and successful mutation screening is essential for developing qualified therapies. The KRAS providers Platform plays a pivotal position During this landscape by giving comprehensive options for KRAS mutation profiling and analysis. KRAS mutations, present in around 95% of RAS-related